NSi-189 powder (1270138-40-3)

There are several clinical trials right now that seem to be linking NSI 189 and the treatment of Major Depressive disorder. The drug is also seen as a promising treatment for neuro-degeneration and other forms of cognitive impairment. The first phase of NSI 189 phosphate powder trials for MDD started in 2011.

The drug was administered to 41 healthy adults. The second part of the first phase then commenced in 2012 where 24 participants were enrolled. The first trails were completed in 2014 and the test results officially released in 2015. The results of the trials showed that NSI 189 failed to meet the primary effectiveness of MDD. Neuralstem also announced in 2017 that another clinical trial involving nearly 220 test subjects also failed to meet the required effectiveness levels for the treatment of MDD.

But there were a few revelations that looked more promising. Detailed reports of these clinical trials found that, even though the drug did not reach the effectiveness levels needed to treat MDD, patients who received up to 40 milligrams a day reported significant improvement in depression.

It was also noted that the 40 mg nsi-189 dose had additional cognitive benefits for patients including improvement in memory. Neuralstem also said that it was looking to pursue NSI 189 as a possible treatment for other neurological conditions including traumatic brain injury, PTSD, as well as cognitive and memory decline in aging.

NSI-189 review articles show that NSI-189 is a drug under trial by a US-based Biotechnology Company called Neuralstem Inc. The drug has been under development for years. The first trials were commenced over seven years ago. At first, NSI 189 was seen as a promising treatment for MDD but so far clinical trials have not proven this. However, there is the potential for NSI 189 to be explored as a Nootropic.

Clinical trials done on patients show that test subjects involved in the trials were able to report significant memory improvements. Whether this is the way the manufacturer wishes to go remains to be seen. But when you consider the setbacks in studying the drug for MDD, exploring it as a possible treatment for memory loss and other cognitive impairments could be the next course of action.

There is very little information about how NSI-189 dopamine works. This is because clinical trials for the drug have been very few and the workings of the drug are not fully understood.

However, from initial research so far, scientists believe that NSI 189 works by promoting neurogenesis in the body. This is the process through which new nerve and brain cells are produced. There is also research showing that NSI 189 has the biggest effect on the hippocampus. This is the area of the brain associated with emotions, memory, and also learning.

So far, some concrete studies on mice have shown that the introduction of NSI 189 may stimulate neurogenesis in the hippocampus. The same results have been replicated in human cell studies as well. But why is this important? If there is continuous cell regeneration in the hippocampus, it means its cognitive functions will be significantly improved. This is the primary reason why NSI-189 examine has shown excellent potential as a possible Nootropic.

Since NSI 189 is an experimental drug, there is no definitive way of determining its positive effect so far. However, certain promising clinical trials may suggest the drug could be used to treat several cognitive issues.
Here is a simple breakdown of all NSI 189 effects:

1.Treatment for Major Depressive Disorder

Even though the trials done by Neuralstem INC showed that NSI 189 did not reach the effective levels needed to treat MDD, the drug showed a lot of promise during the studies. An in-depth analysis of the trial findings showed that people who were treated with the drug during the studies reported significant improvements in depression. What makes this even more interesting is the fact that no serious side effects were reported during the trial phases.

2.Cognitive Improvement

The clinical studies on NSI 189 also revealed that the drug may have a positive effect on improving cognitive function. According to self-reporting questionnaires administered to the test subjects involved in the trials, a significant majority were able to see improvements in memory after taking the drug.
Neuralstem also found that the 220 people involved in the clinical trial showed significant improvements in memory, working memory, and executive function among the study participants. This is the reason why the company is pursuing the drug as a possible treatment for cognitive impairment in the future.

3.Cognitive Issues Associated with Ischemic Stroke

Some studies show NSI 189 may help to improve brain and motor deficits after an ischemic stroke. Although so far these studies have only been done on rats, they are promising. Additionally, trials done on human cells show that NSI 189 may reverse cell death caused by oxygen deprivation.

4.Angleman Syndrome

Angleman Syndrome is a genetic disorder that may affect the nervous system. It may cause seizures, developmental disabilities, and intellectual challenges. Evidence from rat studies shows that NSI 189 may be used to reverse cognitive and movement impairments caused by Angleman Syndrome.

The dosage for NSI 189 is not yet defined since the drug is still experimental. We can only give you information about administration for the clinical trials. So far, the drug is ingested through the mouth. In the trials done over the last seven years, NSI 189 was administered in different doses.

One group of test subjects got a 40 mg NSI-189 dose a day and the other 80 mg a day. There was also a group that was given up to 120 mg a day in NSI-189 dosage. The 40 mg dosage had the best effects on the test subjects, especially in memory improvement. NSI 189 is also sold as a powder and can be combined with fluids before its ingested.

During the clinical trials for NSI 189 curcumin, very few serious side effects were reported. NSI 189 is generally considered a safe drug to use. However, we have seen cases in NSI 189 effects Reddit reviews where users reported experiencing irrational anger after using the drug. NSI 189 may also cause fatigue in some patients, anxiety, drowsiness, social phobia, and headaches. However, these side effects will vary from one individual to another. They are also very manageable and should go away after a few hours. In case side effects persist for longer, seek medical advice.

NSI 189 was developed as a possible treatment for Major Depressive Disorder. A total of two clinical trials have been done over the last seven years but they have not been successful. Test results from clinical trials showed that the drug did not achieve the effectiveness needed to treat MDD. But there were some interesting observations during the trials.

First, NSI 189 had a significant effect in improving depression even if it did not reach the required effectiveness level. The drug also showed promise as a possible treatment for several cognitive issues including memory loss. Additional research to try and prove this is already ongoing. Studies on NSI-189 anxiety are also very promising.

In case you want to leverage the benefits offered by NSI-189 Nootropic, you can buy its powder online. There are so many NSI-189 buy sites but not all of them carry a genuine product. In that case, you may want to take your time. NSI-189 powder suppliers that have some track record of offering quality NSI 189 products should be top in your list.

Check out the reviews of other users too. They will easily help you determine which products to trust and which ones to avoid. NSI 189 anhedonia is an experimental drug so there isn’t a lot of information about it out there. Just take your time and learn more about the drug, its uses, and its effects before you start using it. Get a top NSI 189 powder supplier too and avoid issues.

1.  Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. PubMed PMID: 26643541; PubMed Central PMCID: PMC5030464.
2.  Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 Oct;21(10):1483-4. doi: 10.1038/mp.2016.140. PubMed PMID: 27528461; PubMed Central PMCID: PMC5030463